news
FDA proposes rule officially clearing NAC for dietary supplements
The FDA issued a proposed rule that formally allows N-acetyl-L-cysteine (NAC) in dietary supplements, ending years of legal and retail limbo. The amino acid derivative is a direct precursor to glutathione, the body's primary intracellular antioxidant defense. The move clears retailers and supplement brands to formulate and sell it without regulatory threat.
The FDA issued a proposed rule that formally allows N-acetyl-L-cysteine (NAC) in dietary supplements, ending years of legal and retail limbo. The amino acid derivative is a direct precursor to glutathione, the body's primary intracellular antioxidant defense. The move clears retailers and supplement brands to formulate and sell it without regulatory threat.
The architecture take
I spent two years hoarding NAC capsules in my pantry when Amazon abruptly delisted every bottle back in 2020. Regulators tried arguing that because NAC was approved as an inhaled respiratory drug in 1963, supplement makers had no business selling a 600 mg capsule over the counter. I thought we were watching the start of a permanent land grab on cheap, unpatentable molecules. I admit I was wrong about how stubbornly brands and researchers would push back. The agency folded. This proposed rule settles the long fight. Inside the cell, NAC donates cysteine to synthesize glutathione, clearing reactive oxygen species before they batter your mitochondria and spike systemic inflammation. It also tempers excess glutamate in the brain, which is why clinical trials study it for compulsive loops and brain fog. Now companies can formulate it openly with glycine or milk thistle without keeping lawyers on retainer. My pantry stash can relax.